Annals, Academy of Medicine, Singapore
A randomised controlled study of canagliflozin in improving diabetic kidney disease through a podocyte protection mechanism
By Suping Gu, Najun Zhu, Guojuan Hang and 1 others.
Abstract
Introduction
This study aimed to investigate whether canagliflozin improves diabetic kidney disease (DKD) through a podocyte protective mechanism.
Methods
DKD patients were randomly assigned to the experimental group (87 patients: standard therapy plus cangliflozin 100 mg/day) and the control group (85 patients: standard therapy plus placebo tablets), with a treatment course of 12 weeks. Investigators and outcome assessors were blinded to allocation. Changes in blood glucose, DKD-related indicators (serum albumin, serum creatinine, blood urea nitrogen [BUN], 24-hour urinary protein [24h-UP], urinary albumin-to-creatinine ratio (UACR), and podocyte injury markers (urinary podocyte count, urinary podocalyxin-to-urinary creatinine ratio [UPCX/Ucr]) were compared. Linear mixed-effects models were used to compare intergroup differences, and mediation effect analysis was performed to evaluate the role of UPCX/Ucr in the improvement of DKD-related indicators by canagliflozin.